Skip to search formSkip to main contentSkip to account menu

pracinostat

Known as: 2-propenamide, 3-(2-butyl-1-(2-(diethylamino)ethyl)-1h-benzimidazol-5-yl)-N-hydroxy-, (2E)-, kaempferol 3-o-beta-d-(6-E-P-coumaroylglucoside) 
An orally available, small-molecule histone deacetylase (HDAC) inhibitor with potential antineoplastic activity. Pracinostat inhibits HDACs, which… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminology

Narrower (1)

SB939

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Phase I Study of Pracinostat in Combination with Gemtuzumab Ozogamicin (PraGO) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Background: Relapsed/Refractory AML (RR-AML) represents an area in urgent need for new treatments, particularly among patients… 
2019
2019
PB1746 PRACINOSTAT PLUS AZACITIDINE IN OLDER PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML): A CASE REPORT FROM A PHASE 2 STUDY
2018
2018
Planned Interim Analysis of a Phase 2 Study Evaluating the Combination of Pracinostat, a Histone Deacetylase Inhibitor (HDACi), and Azacitidine in Patients with High/Very High-Risk Myelodysplastic…
Introduction: Higher risk MDS is a serious disease associated with poor survival with hypomethylating agents (HMAs) the… 
2018
2018
Histone Deacetylase Inhibitors in Myelodysplastic Syndrome
Background Myelodysplastic Syndrome (MDS) represents a heterogeneous group of diseases with clonal proliferation, bone marrow… 
Review
2018
Review
2018
Beyond JAK2 Inhibitors: A Systematic Review of Management Strategies for Myelofibrosis
Introduction Drugs that target activating mutations of Janus Kinase 2 (JAK2) have been the backbone of myelofibrosis (MF… 
2017
2017
The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia
Chronic myeloid leukemia (CML) treatment has been improved by tyrosine kinase inhibitors (TKIs) such as imatinib mesylate (IM… 
Review
2016
Review
2016
A Phase 2 Study of Pracinostat and Azacitidine in Elderly Patients with Acute Myeloid Leukemia (AML) Not Eligible for Induction Chemotherapy: Response and Long-Term Survival Benefit
Background: Pracinostat, a potent oral Class I, II, IV histone deacetylase (HDAC) inhibitor, exhibited modest single-agent… 
2014
2014
Pracinostat in Combination with Azacitidine Produces a High Rate and Rapid Onset of Disease Remission in Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Background: Pracinostat is a potent oral inhibitor of histone deacetylases (HDAC’s), selective for class I, II and IV isoforms… 
2014
2014
Abstract 387: Activating transcription factor 3 (ATF-3) expression is a potential marker of tumor response to the HDAC inhibitor Pracinostat
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA BACKGROUND: Bladder cancer is the fifth most common cancer… 
2013
2013
Abstract 2051: PAT-1102, a novel HDAC inhibitor exhibits potent anti-tumor efficacy in patient-derived refractory solid tumors.
Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC Histone deacetylases (HDAC) have been shown to be… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)